Genentech-partnered Genesis Therapeutics inks newest AI discovery deal with Eli Lilly
A Stanford biotech rubbed elbows with Genentech in 2020, reaching a deal with the big-name biotech just over 18 months ago. And now, the AI outfit is in its second partnership with Big Pharma.
Genesis Therapeutics secured a deal with big pharma Eli Lilly, the company announced on Tuesday — to discover therapies “across a range of therapeutic areas,” according to a statement put out by the biotech.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.